| 14 | INVESTMENT IN JOINT VENTURES AND ASSOCIATE | |||||
| 2018 R’000 |
2017 R’000 |
|||||
| 14.1 | INVESTMENT IN JOINT VENTURES | |||||
| The Group has a 49.9% share in Adcock Ingram Limited (India) and a 50% share in National Renal Care Proprietary Limited. The Group's interests in Adcock Ingram Limited (India) and National Renal Care Proprietary Limited are accounted for using the equity method in the consolidated financial statements. The carrying value of the investment is set out below. | ||||||
| Adcock Ingram Limited (India) | 251 155 | 246 019 | ||||
| National Renal Care Proprietary Limited | 193 995 | 145 994 | ||||
| 445 150 | 392 013 | |||||
| 14.2 | INVESTMENT IN ASSOCIATE | |||||
| The Group has a 25.1% share in Ayrton Drug Manufacturing Limited (Ghana), which is accounted for using the equity method in the consolidated financial statements. The carrying value of the investment is set out below: | ||||||
| Cost of investment | 5 133 | 5 133 | ||||
| Share of post acquisition profit | 3 969 | 1 548 | ||||
| Exchange rate adjustments | (1 088) | (610) | ||||
| 8 014 | 6 071 |